<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25387507</article-id>
      <article-id pub-id-type="pmc">4230671</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20143128</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Refractory pemphigus vulgaris treated with rituximab and mycophenolate
mofetil<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Biot</surname>
            <given-names>Stephanie Del Rio Navarrete</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Franco</surname>
            <given-names>Joanna Pimenta de Araujo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Ricardo Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Henrique Novo Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marques</surname>
            <given-names>Luiz Paulo Jos&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Carlos Jos&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label> Universidade Federal do Estado do Rio de Janeiro (UNIRIO) - Rio de
Janeiro (RJ), Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><italic>MAILING ADDRESS:</italic> Stephanie Del Rio Navarrete Biot, Rua Mariz e
Barros, 775 - Tijuca, 20270-004 - Rio de Janeiro - RJ, Brazil. E-mail:
<email>tupibiot@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>6</issue>
      <fpage>980</fpage>
      <lpage>984</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>The main treatment for pemphigus vulgaris are systemic corticosteroids and
immunosuppressive agents, but due to adverse reactions and therapeutic failure, new
drugs such as rituximab and mycophenolate mofetil have been used. In this case report
are described two cases of severe pemphigus vulgaris refractory to various
treatments, with resolution after use of rituximab and mycophenolate mofetil,
associated with corticosteroids. A higher-than-usual dose of rituximab was employed,
without the occurrence of serious adverse reactions. Mycophenolate mofetil was added
as adjunctive therapy due to lack of response to azathioprine.</p>
      </abstract>
      <kwd-group>
        <kwd>Antibodies, monoclonal</kwd>
        <kwd>Immunosuppressive agents</kwd>
        <kwd>Pemphigus</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Pemphigus vulgaris (PV) is a potentially fatal autoimmune bullous disease with a
mortality rate around 5%.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> The main
treatment are systemic corticosteroids associated with immunosuppressants, but due to
adverse reactions and treatment failure new therapeutic drugs have been prescribed, such
as rituximab<sup><xref rid="r02" ref-type="bibr">2</xref></sup> and mycophenolate
mofetil (MMF).<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup> Rituximab is an anti-CD20 monoclonal antibody that causes
the depletion of B lymphocytes and B pre-lymphocytes. Initially developed for the
treatment of non-Hodgkin lymphoma, it has been shown to be an excellent option for
autoimmune diseases like PV.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> MMF is a
relatively new immunosuppressant.<sup><xref rid="r03" ref-type="bibr">3</xref></sup> It
acts by specifically inhibiting activated T lymphocytes, with a more selective action,
and with the advantage of being less mutagenic regarding azathioprine.<sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> Its use is approved for the prevention of
solid organs allograft rejection and for lupus nephritis. Several studies point out its
efficacy in the treatment of PV.<sup><xref rid="r04" ref-type="bibr">4</xref>-<xref rid="r08" ref-type="bibr">8</xref></sup> In this current study two cases of severe
PV are reported, refractory to diverse treatments, with clinical resolution after use of
rituximab and MMF combined with corticotherapy.</p>
    </sec>
    <sec>
      <title>CASE REPORTS</title>
      <p>Case 1 - Male, 47 years old, with diagnosis of PV and using prednisone 120mg/day for one
month. At the examination he presented eroded and crusted lesions disseminated on the
skin and erosions in the oral mucosa. Diagnosis of PV was histologically confirmed.
Treatment was begun with pulses of methylprednisolone IV and oral prednisone between
pulses. The patient progressed rapidly with severe worsening and infusions of
intravenous immunoglobulin combined with prednisone and oral azathioprine were
introduced (<xref ref-type="fig" rid="f01">Figure 1A</xref>). After a period of
improvement new lesions appeared and pulses of cyclophosphamide IV were administered,
continuing with oral prednisone. Again there was improvement but after the fourth pulse
a severe relapse occurred. Plasmapheresis was performed as well as a new pulse of
cyclophosphamide with good response, but after seven days there was onset of new lesions
(<xref ref-type="fig" rid="f01">Figure 1B</xref>). At this point, treatment with
rituximab was initiated. Prednisone was maintained and MMF was added. After the second
cycle there was complete resolution of the clinical picture with hospital discharge,
main-taining prednisone and MMF (<xref ref-type="fig" rid="f01">Figure 1C</xref>). The
patient was hospitalized for eight months and presented severe complications like
infections and sepsis, before the initiation of rituximab, making use of several schemes
of antibiotic therapy. During the outpatient clinic follow-up the MMF dose was
maintained and the dose of prednisone was progressively reduced in the course of one
year, until suspension. At this point, oral lesions appeared which persisted even after
increase of prednisone. A new infusion of rituximab was started and the dose of MMF was
increased, with resolution of lesions. One year after the last cycle of rituximab, the
patient remains with the disease controlled with MMF 2.5g/day and prednisone 10mg on
alternate days. The therapeutic steps with drugs, doses, intervals and duration, are
described in <xref ref-type="table" rid="t01">table 1</xref>.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p><bold>(CASE 1): A:</bold> extensive erosion of lesions on the trunk and limbs, in
the first phase of exacerbation of the disease before beginning treatment with
intravenous immunoglobulin. <bold>B:</bold> dorsolumbar region after
plasmapheresis, before beginning treatment with rituximab. <bold>C:</bold>
dorsolumbar region after the end of second cycle of rituximab, three months after
the first infusion</p>
        </caption>
        <graphic xlink:href="abd-89-06-0980-g01"/>
      </fig>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Therapeutic phases - case 1</p>
        </caption>
        <table frame="hsides" rules="groups">
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Phases</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Medications</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Period</bold>
              </td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">1st</td>
              <td valign="top" rowspan="1" colspan="1">2 cycles of pulse therapy with MPD 1g IV, for 3 days, with
weekly interval and PDN 60 mg/day, between pulses.</td>
              <td valign="top" rowspan="1" colspan="1">2 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">2nd</td>
              <td valign="top" rowspan="1" colspan="1">3 cycles of infusions of IVIG 2g/kg/cycle, divided in 4 days,
with intervals of 2 to 3 weeks, PDN 120mg/day and AZA 150mg/day.</td>
              <td valign="top" rowspan="1" colspan="1">9 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">3rd</td>
              <td valign="top" rowspan="1" colspan="1">4 pulses of CPP 500mg/m<sup>2</sup> IV, with interval of 3
weeks between pulses and PDN 120mg/day.</td>
              <td valign="top" rowspan="1" colspan="1">9 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">4th</td>
              <td valign="top" rowspan="1" colspan="1">3 sessions of PPH with 1 pulse of CPP on fourth day, and PDN
120mg/day</td>
              <td valign="top" rowspan="1" colspan="1">2 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">5th</td>
              <td valign="top" rowspan="1" colspan="1">RTX, 2 cycles of 4 weekly infusions of 375mg/m<sup>2</sup>,
with 4-week intervals between cycles, PDN 120mg/day and MMF 2g/day. Hospital
discharge after 8 months.</td>
              <td valign="top" rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">6th</td>
              <td valign="top" rowspan="1" colspan="1">Outpatient clinic treatment with MMF 2g/day and progressive
reduction of PDN dose for 1 year, until suspension, when relapse of lesions
occurred, refractory to reintroduction of PDN 80mg/day.</td>
              <td valign="top" rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">7th</td>
              <td valign="top" rowspan="1" colspan="1">New hospitalization for administration of RTX, 1 cycle of two
infusions of 1g, with a two-week interval, PDN 80mg/day and MMF 2.5g/day.
Hospital discharge after 4 weeks.</td>
              <td valign="top" rowspan="1" colspan="1">4 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">8th</td>
              <td valign="top" rowspan="1" colspan="1">Outpatient clinic treatment with progressive reduction of PDN
dose. One year after the last RTX infusion, the disease remains controlled
with MMF 2.5mg and PDN 10mg on alternate days.</td>
              <td valign="top" rowspan="1" colspan="1">12 weeks</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Note: MPD = methylprednisolone; PDN = prednisone; IVIG = intravenous
immunoglobulin; AZA = azathioprine; CPP = cyclophosphamide; PPH =
plasmapheresis; RTX = rituximab; MMF = mycophenolate mofetil.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Case 2 - Female, 46 years old, with hypertension and diabetes, both difficult to
control, presented bullous lesions and erosions, with purulent secretion, disseminated
on the scalp, face, trunk and limbs. Diagnosis of PV was confirmed histologically. She
was hospitalized and submitted to treatment with antibiotic therapy, pulses of
methylprednisolone IV and pulses of cyclophosphamide IV, with monthly intervals, besides
oral prednisone and azathioprine. She achieved almost complete remission of lesions
after the second pulse of cyclophosphamide, with hospital discharge. After the fifth
pulse she presented leucopenia and after the sixth pulse there was relapse of the
disease (<xref ref-type="fig" rid="f02">Figure 2A</xref>). The patient was hospitalized
again and rituximab infusions were administered with two-week intervals, maintaining
oral prednisone and azathioprine. There was improvement in the trunk lesions, but
worsening of the facial ones, even after the third infusion of rituximab (<xref ref-type="fig" rid="f02">Figures 2B</xref> and <xref ref-type="fig" rid="f03">3A</xref>). As a consequence, together with the fourth infusion the prednisone dose
was increased and azathioprine replaced with MMF, with progressive improvement and
hospital discharge after two months of hospitalization (<xref ref-type="fig" rid="f03">Figure 3B</xref>). Since then the prednisone dose was progressively reduced and two
years after hospital discharge, the patient remains with the disease under control with
MMF 1g/day and prednisone 5mg/day (<xref ref-type="fig" rid="f03">Figure 3C</xref>). The
therapeutic steps, with drugs, doses, intervals and duration, are described in <xref ref-type="table" rid="t02">table 2</xref>.</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>(CASE 2): A:</bold> erosions in dorsolumbar region after relapse of the
disease, during pulse therapy with cyclophosphamide plus prednisone and
azathioprine orally. <bold>B:</bold> improvement of lesions in dorsolumbar region,
after the third rituximab A B infusion</p>
        </caption>
        <graphic xlink:href="abd-89-06-0980-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p><bold>(CASE 2): A:</bold> erosions on face and scalp, after the third rituximab
infusion. <bold>B:</bold> healing of lesions on the face three weeks after the
fourth rituximab infusion, increase of prednisone dose and introduction of MMF.
<bold>C:</bold> face and scalp 18 months after the end of rituximab
infusions</p>
        </caption>
        <graphic xlink:href="abd-89-06-0980-g03"/>
      </fig>
      <table-wrap id="t02" orientation="portrait" position="float">
        <label>TABLE 2</label>
        <caption>
          <p>Therapeutic phases - case 2</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">
                <bold>Phases</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>Medications</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>Duration</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" rowspan="1" colspan="1">1st</td>
              <td valign="top" rowspan="1" colspan="1">Pulse therapy with MPD lg/day IV, for 3 days, and 6 pulses CPP
500mg/m2 IV, with monthly intervals and PDN 30mg/day and oral AZA 150mg/day
between pulses. Hospital discharge after second pulse of CPP. Following
pulses in a day-hospital schedule.</td>
              <td valign="top" rowspan="1" colspan="1">22 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">2nd</td>
              <td valign="top" rowspan="1" colspan="1">New hospitalization for administration of RTX, 4 infusions of
lg, with 15-day interval, continuing PDN 30mg/day and AZA 150mg/day up to
the 4th infusion. With the 4th infusion, PDN was increased to 80mg/day and
AZA was replaced by MMF 1.5g/day. Hospital discharge after 2 months.</td>
              <td valign="top" rowspan="1" colspan="1">9 weeks</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">3rd</td>
              <td valign="top" rowspan="1" colspan="1">Outpatient clinic treatment with MMF 1.5g/day and progressive
decrease of PDN dose. Two years after the last RTX infusion, the disease
remains controlled with MMF 1g/day and PDN 5mg/day.</td>
              <td valign="top" rowspan="1" colspan="1">24 weeks</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Note: MPD = methylprednisolone; CPP = cyclophosphamide; PDN = prednisone; AZA =
azathioprine; RTX = rituximab; MMF = mycophenolate mofetil.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Rituximab is indicated mainly for patients with PV refractory to at least two
therapeutic modalities.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> The most used schemes are the four
infusions per week at a dose of 375mg/m<sup><xref rid="r02" ref-type="bibr">2</xref></sup>; and the one of two infusions of 1g with two-week interval. They are
approved, respectively, for the treatment of B cell non-Hodgkin lymphomas, and for
rheumatoid arthritis refractory to therapy with anti-TNF&#x3B1;.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> The most common collateral effects are related to
infusion (headache, fever, nausea, vomiting, pruritus, hypotension). Severe effects such
as sepsis and opportunistic infections are rare.<sup><xref rid="r09" ref-type="bibr">9</xref></sup> In a study of 103 patients with PV who were treated with
rituximab, Schmidt and collaborators reported complete remission in 77% and partial
remission in 21% of the patients. Severe collateral effects occurred in 14% of the
patients.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> In the two cases
reported in this work a greater number of infusions of rituximab were necessary until
the resolution of lesions, with no occurrence of adverse reactions.</p>
      <p>MMF is considered by some authors the best corticosteroid-sparing drug for bullous
diseases.<sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup> The recommended dose is 35mg-45mg/kg/day, administered
every 12 hours with meals. The dose should be gradually increased to avoid
gastrointestinal effects.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup>
The drug is presented in 500mg capsules and there is another form, sodium mycophenolate,
presented in 360mg capsules, equivalent to 500mg of MMF.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>In a study with 36 cases of patients with PV and pemphigus foliaceus treated with
rituximab, the most used concomitant drugs were prednisone and MMF, in 53% and 50% of
the cases, respectively.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>The high cost and the <italic>off-label</italic> condition are factors that limit its
provision by Unified Health System (SUS - Sistema &#xDA;nico de Sa&#xFA;de). In the reported
cases, rituximab was supplied by the hospital unit and the MMF by the nephrology sector,
until obtained by SUS with a judicial warrant.</p>
      <p>The reports in the literature and the results obtained in the described cases indicate
that rituximab and MMF are safe, effective drugs, with lasting results, revealing
themselves as valuable therapeutic options for severe and refractory PV. <sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Biot SDRN, Franco JPA, Lima RB, Pereira HNC, Marques LPJ,
Martins CJ. Refractory pemphigus vulgaris treated with rituximab and mycophenolate
mofetil. An Bras Dermatol. 2014;89(6):980-4.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work carried out at the Hospital Universit&#xE1;rio Gaffr&#xE9;e e Guinle, Universidade
Federal do Estado do Rio de Janeiro (UNIRIO) - Rio de Janeiro (RJ), Brasil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sorce</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aric&#xF2;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bongiorno</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Rituximab in refractory pemphigus vulgaris</article-title>
          <source>Dermatol Ther</source>
          <year>2008</year>
          <volume>21</volume>
          <issue>Suppl 1</issue>
          <fpage>S6</fpage>
          <lpage>S9</lpage>
          <pub-id pub-id-type="pmid">18727815</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goebeler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zillikens</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Rituximab in severe pemphigus</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2009</year>
          <volume>1173</volume>
          <fpage>683</fpage>
          <lpage>691</lpage>
          <pub-id pub-id-type="pmid">19758216</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Karashima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yasumoto</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Sucessful treatment with mycophenolate mofetil of four Japanese
patients with pemphigus vulgaris</article-title>
          <source>Eur J Dermatol</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>472</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="pmid">20406724</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bressan</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Fontenelle</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gripp</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppressive agents in Dermatology</article-title>
          <source>An Bras Dermatol</source>
          <year>2010</year>
          <volume>85</volume>
          <fpage>9</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">20464082</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orvis</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Wesson</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Breza</surname>
              <given-names>TS</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Church</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Mycophenolate mofetil in dermatology</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2009</year>
          <volume>60</volume>
          <fpage>183</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">19150270</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beissert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Werfel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Frieling</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>B&#xF6;hm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sticherling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stadler</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A comparison of oral methylprednisolone plus azathioprine or
mycophenolate mofetil for the treatment of pemphigus</article-title>
          <source>Arch Dermatol</source>
          <year>2006</year>
          <volume>142</volume>
          <fpage>1447</fpage>
          <lpage>1454</lpage>
          <pub-id pub-id-type="pmid">17116835</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esmaili</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chams-Davatchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Valikhani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farshidfar</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Parvaneh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tamizifar</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Treatment of pemphigus vulgaris with mycophenolate mofetil as a
steroid-sparing agent</article-title>
          <source>Eur J Dermatol</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>159</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="pmid">18424375</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Powell</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Al Fares</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Harman</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Setterfield</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bhogal</surname>
              <given-names>B</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>An evaluation of the usefulness of mycophenolate mofetil in
pemphigus</article-title>
          <source>Br J Dermatol</source>
          <year>2003</year>
          <volume>149</volume>
          <fpage>138</fpage>
          <lpage>145</lpage>
          <pub-id pub-id-type="pmid">12890207</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hunzelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zillikens</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Br&#xF6;cker</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Goebeler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Rituximab in refractory autoimmune bullous diseases</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2006</year>
          <volume>31</volume>
          <fpage>503</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="pmid">16716150</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasperkiewicz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eming</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Behzad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hunzelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Meurer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schulze-Koops</surname>
              <given-names>H</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Efficacy and safety of rituximab in pemphigus: experience of the
german registry of autoimmune diseases</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>727</fpage>
          <lpage>732</lpage>
          <pub-id pub-id-type="pmid">22577946</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
